Published in:
01-10-2021 | Letters to the Editor
Comment on “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma”
Published in: Investigational New Drugs | Issue 5/2021
Login to get accessAbstract
Recently, we read a paper “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma” published in Investigational New Drugs. Quisinostat may be a promising drug candidate for the treatment of esophageal squamous cell carcinoma. However, some problems existing in the methods part of this paper are worthy of comment.